Clinical Trial Update: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tumor treating fields with weekly paclitaxel for recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• TTFields (tumor treating fields) therapy

Snippet

Sponsor: NovoCure Ltd. | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED